Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | DHPS | P49366 | 8/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.47 |
| ▸ | JAK3 | P52333 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25120814 | 0.84 | DHPS (0.57) | MAPK1DHPSTRPV1HDAC1HDAC3 | |
| SCHEMBL4865185 | 0.82 | MAPK1 (0.54) | MAPK1DHPSALDH1A1TRPV1HDAC1 | |
| SCHEMBL4025098 | 0.80 | MAPK1 (0.63) | MAPK1DHPSTRPV1HTR6 | |
| SCHEMBL29901215 | 0.80 | MAPK1 (0.63) | MAPK1DHPSTRPV1HTR6 | |
| SCHEMBL13046884 | 0.79 | MAPK1 (0.61) | MAPK1DHPSALDH1A1TRPV1MEN1 | |
| SCHEMBL257380 | 0.79 | MAPK1 (0.71) | MAPK1DHPSALDH1A1TRPV1HDAC1 | |
| SCHEMBL29107208 | 0.79 | MAPK1 (0.50) | MAPK1DHPSALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL22828692 | 0.77 | HDAC1 (0.55) | MAPK1DHPSALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL7434190 | 0.76 | ALDH1A1 (0.56) | MAPK1DHPSALDH1A1LMNAHTT | |
| SCHEMBL29107174 | 0.76 | TRPV1 (0.54) | MAPK1DHPSSMN1; SMN2TRPV1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022132609-A1 | MOLECULES HAVING CERTAIN PESTICIDAL UTILITIES, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES RELATED THERETO | CORTEVA AGRISCIENCE LLC (US) | 2022-06-23 | — | — | WO | disclosed |
| US-7407960-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2008-08-05 | — | — | US | disclosed |
| EP-1806346-A1 | Substituted piperazine compounds and their use as fatty acid oxidation inhibitors | CV THERAPEUTICS, INC. (US) | 2007-07-11 | — | — | EP | disclosed |
| EP-1567525-B1 | SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS INC (US) | 2007-06-27 | — | — | EP | disclosed |
| US-20070004751-A1 | Substituted heterocyclic compounds | ELZEIN ELFATIH | 2007-01-04 | — | — | US | disclosed |
| US-7125876-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2006-10-24 | — | — | US | disclosed |
| US-20040152890-A1 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. | 2004-08-05 | — | — | US | disclosed |
| CN-1297439-A | 4-amino-(ethylamino)-oxindole dopamine autoreceptor agonists | AMERICAN HOME PROD (US) | 2001-05-30 | — | — | CN | disclosed |
| US-6228880-B1 | PARKINSON*S DISEASE, TOURETTE*S SYNDROME, SCHIZOPHRENIA, ALCOHOLISM, DRUG ABUSE; SIDE EFFECT REDUCTION | AMERICAN HOME PRODUCTS CORP | 2001-05-08 | — | — | US | disclosed |
| EP-1073636-A1 | 4-AMINO-(ETHYLAMINO)-OXINDOLE DOPAMINE AUTORECEPTOR AGONISTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-02-07 | — | — | EP | disclosed |
| WO-1999052870-A1 | 4-AMINO-(ETHYLAMINO)-OXINDOLE DOPAMINE AUTORECEPTOR AGONISTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152890-A1 | Substituted heterocyclic compounds | KCNH1, SDHA, COQ8A | MAPK1 3310/4885DHPS 244/4885ALDH1A1 245/4885 |
| US-20070004751-A1 | Substituted heterocyclic compounds | KCNH1, SDHA, COQ8A | MAPK1 3207/4885DHPS 215/4885ALDH1A1 281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.